Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]

Detalles Bibliográficos
Autores principales: Crothers, Jessica W., Ross Colgate, Elizabeth, Cowan, Kelly J., Dickson, Dorothy M., Walsh, MaryClaire, Carmolli, Marya, Wright, Peter F., Norton, Elizabeth B., Kirkpatrick, Beth D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2022
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168436/
https://www.ncbi.nlm.nih.gov/pubmed/35534312
http://dx.doi.org/10.1016/j.vaccine.2022.05.001
_version_ 1784721008163291136
author Crothers, Jessica W.
Ross Colgate, Elizabeth
Cowan, Kelly J.
Dickson, Dorothy M.
Walsh, MaryClaire
Carmolli, Marya
Wright, Peter F.
Norton, Elizabeth B.
Kirkpatrick, Beth D.
author_facet Crothers, Jessica W.
Ross Colgate, Elizabeth
Cowan, Kelly J.
Dickson, Dorothy M.
Walsh, MaryClaire
Carmolli, Marya
Wright, Peter F.
Norton, Elizabeth B.
Kirkpatrick, Beth D.
author_sort Crothers, Jessica W.
collection PubMed
description
format Online
Article
Text
id pubmed-9168436
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-91684362022-06-14 Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713] Crothers, Jessica W. Ross Colgate, Elizabeth Cowan, Kelly J. Dickson, Dorothy M. Walsh, MaryClaire Carmolli, Marya Wright, Peter F. Norton, Elizabeth B. Kirkpatrick, Beth D. Vaccine Corrigendum Elsevier Science 2022-05-31 /pmc/articles/PMC9168436/ /pubmed/35534312 http://dx.doi.org/10.1016/j.vaccine.2022.05.001 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Corrigendum
Crothers, Jessica W.
Ross Colgate, Elizabeth
Cowan, Kelly J.
Dickson, Dorothy M.
Walsh, MaryClaire
Carmolli, Marya
Wright, Peter F.
Norton, Elizabeth B.
Kirkpatrick, Beth D.
Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title_full Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title_fullStr Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title_full_unstemmed Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title_short Corrigendum to “Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [Vaccine 40(19) (2022) 2705–2713]
title_sort corrigendum to “intradermal fractional-dose inactivated polio vaccine (fipv) adjuvanted with double mutant enterotoxigenic escherichia coli heat labile toxin (dmlt) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial” [vaccine 40(19) (2022) 2705–2713]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168436/
https://www.ncbi.nlm.nih.gov/pubmed/35534312
http://dx.doi.org/10.1016/j.vaccine.2022.05.001
work_keys_str_mv AT crothersjessicaw corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT rosscolgateelizabeth corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT cowankellyj corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT dicksondorothym corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT walshmaryclaire corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT carmollimarya corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT wrightpeterf corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT nortonelizabethb corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac
AT kirkpatrickbethd corrigendumtointradermalfractionaldoseinactivatedpoliovaccinefipvadjuvantedwithdoublemutantenterotoxigenicescherichiacoliheatlabiletoxindmltiswelltoleratedandaugmentsasystemicimmuneresponsetoallthreepoliovirusserotypesinarandomizedactivecontrolledtrialvac

Ejemplares similares